Replimune Group (NASDAQ:REPL) Sets New 12-Month High – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $14.14 and last traded at $13.65, with a volume of 4763199 shares traded. The stock had previously closed at $13.67.

More Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million financing strengthens Replimune’s balance sheet. The company priced an underwritten offering of 9,701,490 common shares and pre-funded warrants for another 2,736,340 shares at approximately $12.06 per share. Proceeds are expected to support development and commercialization of its oncolytic immunotherapies, including its FDA-approved melanoma treatment. Replimune Announces Pricing of $150 Million Underwritten Offering
• Positive Sentiment: Shares rose following the offering pricing. The market may be interpreting the capital raise as reducing near-term funding concerns and providing resources for product development and commercialization, although the offering is also dilutive. Replimune Shares Rise After Pricing of Offering
• Positive Sentiment: Regulatory progress remains a major catalyst. Replimune’s RP1 therapy received FDA approval for advanced melanoma, easing a significant regulatory uncertainty and expanding the company’s commercial opportunity. Why Replimune Stock Has Surged
• Neutral Sentiment: Analyst sentiment is mixed. One report cited a price-target increase to $20, but other recent ratings and targets have been considerably more cautious. This suggests substantial disagreement about the company’s valuation and commercial execution.
• Negative Sentiment: Several law firms publicized a securities-fraud class action against Replimune and certain officers. The lawsuit covers investors who purchased shares from October 20, 2025, through April 10, 2026, and alleges violations of federal securities laws. The announcements increase headline and potential legal risk, although the allegations have not been proven. Investors have until October 5, 2026, to seek lead-plaintiff status. Replimune Class Action Announcement
• Negative Sentiment: The equity offering will dilute existing shareholders. The issuance of more than 12.4 million shares and share-equivalent warrants increases the company’s share count, potentially limiting per-share upside despite improving liquidity.

Analyst Ratings Changes

REPL has been the subject of several research reports. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a research note on Friday. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. raised their price target on Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.86.

Replimune Group Price Performance

The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -4.04 and a beta of 0.88. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The company’s fifty day moving average is $10.34 and its two-hundred day moving average is $7.64.

Replimune Group (NASDAQ:REPL) last released its earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Equities research analysts anticipate that Replimune Group, Inc. will post -2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently added to or reduced their stakes in REPL. ProShare Advisors LLC lifted its holdings in Replimune Group by 10.3% during the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after acquiring an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Replimune Group by 4.7% in the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after acquiring an additional 1,712 shares during the period. Ballentine Partners LLC increased its holdings in shares of Replimune Group by 7.8% in the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after acquiring an additional 1,721 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares in the last quarter. Finally, Walleye Capital LLC increased its holdings in shares of Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after acquiring an additional 2,192 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.